Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[ATM/H2AX and repair of sperm-DNA damage during cryopreservation].

Zhonghua nan ke xue = National journal of andrology·2011

Same author

Predicting accident frequency at their severity levels and its application in site ranking using a two-stage mixed multivariate model.

Accident; analysis and prevention·2011

Same author

Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide.

ACS nano·2011

Same author

[Characteristics of soil respiration in Phyllostachys edulis forest in Wanmulin Natural Reserve and related affecting factors].

Ying yong sheng tai xue bao = The journal of applied ecology·2011

Same author

Quality changes in sea urchin (Strongylocentrotus nudus) during storage in artificial seawater saturated with oxygen, nitrogen and air.

Journal of the science of food and agriculture·2011

Same author

Global effect of an RNA polymerase β-subunit mutation on gene expression in the radiation-resistant bacterium Deinococcus radiodurans.

Science China. Life sciences·2011

Search research articles

Related Experiment Video

Updated: Oct 13, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Engineered biomaterials for cancer immunotherapy.

Lulu Cai¹, Jialu Xu², Zhenglin Yang³

¹Personalized Drug Therapy Key Laboratory of Sichuan Province Department of Pharmacy Sichuan Provincial People's Hospital School of Medicine University of Electronic Science and Technology of China Chengdu China.

|November 12, 2021

Summary

Cancer immunotherapy shows promise but has limited efficacy and side effects. Localized delivery using engineered biomaterials can improve anticancer immunity and reduce adverse effects by targeting treatment directly to the tumor site.

Keywords:

anticancer immunity biomaterials cancer immunotherapy localized delivery

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Related Experiment Videos

Last Updated: Oct 13, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Area of Science:

Biomedical Engineering
Immunology
Materials Science

Background:

Cancer immunotherapy offers significant therapeutic potential but faces challenges with limited patient response and systemic toxicity.
Current immunotherapies often suffer from poor drug selectivity and require high doses, leading to undesirable side effects.
Localized delivery strategies aim to overcome these limitations by concentrating therapeutic agents at the tumor site.

Purpose of the Study:

To review the advancements in engineered biomaterials for localized cancer immunotherapy.
To highlight the role of biomaterials in developing effective and safe localized cancer treatments.
To summarize the application of biomaterials in activating anticancer immunity in situ.

Main Methods:

Review of scientific literature on engineered biomaterials for localized drug delivery in cancer immunotherapy.
Analysis of different biomaterial fabrication methods (implantable, injectable, transdermal) for drug delivery devices.
Synthesis of current progress in applying these materials for in situ immune activation.

Main Results:

Engineered biomaterials are crucial for creating localized delivery systems for cancer immunotherapy.
Biomaterials enable controlled release of immunomodulators, enhancing anticancer immunity directly at the tumor.
Localized delivery strategies mitigate systemic immune overactivation and reduce treatment-related side effects.

Conclusions:

Engineered biomaterials are pivotal in advancing localized cancer immunotherapy.
These materials facilitate targeted delivery of immunomodulators, improving therapeutic efficacy and safety.
Further development of biomaterial-based delivery systems holds promise for more effective cancer treatment.